tbuckley/cabot-search huggingface dataset:
Correction:Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy
Authors: Dmitriy Zamarin, Howard L Kaufman, Dobrin Draganov, Sofia R Gameiro, Ilio Vitale, Sandy Adjemian, Aitziber Buqué Martinez, Timothy A Chan, Richard L Edelson, Lucia Gabriele, Encouse Golden, Kevin J Harrington, Dewan Md Sakib Hossain, Michael Karin, Juan Jose Lasarte, Sherene Loi, Gwenola Manic, Alan A Melcher, Karen L Mossman, Maria Rescigno, Chiara Riganti, Antonella Sistigu, Bryan E Strauss, Kazuki Tatsuno, Stefaan W van Gool, Peter Vandenabeele
Journal: Journal for ImmunoTherapy of Cancer (2020)
Gynecologic Endocrinology
Authors: Irwin E. Thompson
Journal: JAMA (1987)

The fourth edition of<i>Gynecologic Endocrinology</i>maintains the excellence of the prior editions and can be definitely recommended. It is organized into six major areas with 34 chapters written by a long list of acknowledged authorities. Parts 1 and 2 deal with basic neuroendocrinology and hormonal physiology, including placental endocrinology and the physiology of relaxin. Thyroid function and diseases in women are also completely covered in a single well-written chapter. Part 3 covers diagnostic procedures and is perhaps the most uneven portion of the book, owing mostly to extreme variations in the length of the individual chapters. Within this group, the chapter on hormonal cytopathology of the vagina is interesting, but probably over-interprets the usefulness of this methodology in the light of more modern assay techniques. The chapter on endoscopic procedures is succinct, but almost too short. Part 4 covers women's endocrine disorders in 15 separate chapters. This portion is
THE COURTS AND THE MILK SUPPLY
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Amphetamine-like reactions to phenylpropanolamine
Authors: A. J. Dietz
Journal: JAMA (1981)

Phenylpropanolamine hydrochloride is an amphetamine-like substance that is found in 64 different over-the-counter preparations for colds and appetite suppression. It is also found in numerous prescription drugs. Recently, it has been reported to cause symptoms of sympathomimetic-like effects, such as severe hypertension, hypertensive crisis, and possible renal failure. Also, several cases of psychotic episodes while taking phenylpropanolamine have been reported. This is the report of seven patients who have experienced acute CNS effects. These effects range from stimulation of the medullary respiratory center to tremor, restlessness, increased motor activity, agitation, and hallucinations. (<i>JAMA</i>1981;245:601-602)
Abstract 3704: CRISPR screening in a xenograft model for <i>in vivo</i> drug moa analysis
Authors: Michele Melton, Athena Bast, Alastair Leeson-Payne, Maximilian Blanck, Steffen Lawo, Deeds Stacy, Benedict C.S. Cross
Journal: Cancer Research (2019)

Abstract Functional genomic screening with CRISPR has provided a powerful and precise new way to interrogate the phenotypic consequences of gene manipulation in high-throughput, unbiased analyses. Rapid development of pooled lentivirus and deep-sequencing-led approaches have allowed us and others to exploit this technology in target ID, target validation, drug MOA analysis and patient stratification.Until now, these exquisitely powerful screening technologies have been deployed predominantly in simple in vitro analyses. Whilst these in vitro approaches allow for high quality hit discovery and at whole-genome level scale, they are not able to adequately capture the impact of tumour microenvironment and heterogeneity on the genetic perturbations under study. To address this, we present here the development and validation of a platform for pooled CRISPR knock-out screening in xenograft models of tumour growth. A critical step in appropriate study design is the evaluation of the cell uptake following implantation. Since this directly contributes to the tumour growth and cell number, understanding cell survival dynamics post-implantation is necessary to determine the appropriate experimental scope. We used a barcoding approach coupled to next generation sequencing to determine the response and contribution of individual A375 melanoma cells to final tumour composition and used this to calibrate the experimental design for robust pooled-based CRISPR screening analysis. Following the determination of experimental conditions, a proof-of-concept drug mechanism of action analysis was conducted using a custom designed cancer genome CRISPR knock-out library. A375 cells were first infected with the CRISPR library and selected ex vivo ahead of implantation and treatment of established tumour-bearing nude mice with a defined therapeutic regime of the BRAFV600E selective inhibitor, Vemurafenib. Tumours were harvested and the identification of genes which selectively modulate the tumour response to drug were identified by next generation sequencing using our optimised screening analysis platform. Our results provide a robust experimental validation and define a novel platform which will allow the rapid and definitive in vivo evaluation of both drug and gene interactions using powerful CRISPR-based screening tools. Citation Format: Michele Melton, Athena Bast, Alastair Leeson-Payne, Maximilian Blanck, Steffen Lawo, Deeds Stacy, Benedict C.S. Cross. CRISPR screening in a xenograft model for in vivo drug moa analysis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3704.
Histamine releasability of basophils and skin mast cells in chronic urticaria
Authors: T. Zuberbier, S. Schwarz, K. Hartmann, C. Pfrommer, B. M. Czarnetzki
Journal: Allergy (1996)

In order to clarify the pathogenetic role of basophils and mast cells in chronic urticaria, histamine and leukotriene (LT)C4 release was examined in washed mixed leukocytes (n= 8) and skin mast cells (n= 5) from patients with chronic urticaria and compared with the same cells from normal controls (n= 9). Anti-IgE-stimulated basophil histamine release was significantly reduced in urticaria patients (median 2.9%vs 15.1% in normal controls), whereas histamine release to A23187. FMLP, and PAF, as well as anti-IgE-induced LTC4 release, showed no differences in both groups. In contrast, anti-IgE-stimulated skin mast cells from urticaria patients reacted similarly to those of controls (median histamine release 11.4%vs 14.2% in normal controls). Pretreatment of the cells with interleukin (IL)-3 upregulated responsiveness of basophil histamine release to anti-IgE in urticaria patients (median histamine release 14.3%), but pretreatment with the H2-antagonist cimetidine showed no effect. These data show that reduced basophil histamine releasability in chronic urticaria is not H2 mediated. It is a stimulus, mediator-, and cell type-restricted phenomenon that can, at least partially, be reversed in the presence of the cytokine IL-3.
Erratum
Journal: BMJ (1899)

MEDICAL JOURNAL of May 2oth, may I suggest to him the possibility of the trouble being connected with uric acid diathesis as I have recently seen two cases with similar symptoms relieved only by the administration internally of alkalies, of potass.biearb.gr xv ter in die, by preference, taken with a tumblerful of moderately hot water on each ocvasion, combined with the protection of the nasal mucous membrane by the use of an oil spray.An excellent form of this is the nasal cloudiser manufactured by Messrs. Slater Brothers, of Baker Street.W., and the application which relieved my patients consisted of ichthyol 3j dissolved in ol.amygdal.dulc.3vij, the resulting solution being strained before lise.Should the suggestion contained in the JOURGNAL of May 27th fail to afford relief, A Medical Correspondent " mnight feel disposed to try this method.
Albatross Colony Yields New Virus
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Chromosome Aberrations in Cultured Peripheral Lymphocytes from Persons with Elevated Skin Radiosensitivity
Authors: Tatiana V. Kondrashova, Tatiana I. Ivanova, Sergei N. Katsalap
Journal: Environmental Health Perspectives (1997)

The purpose of this study was to elucidate whether an enhanced skin radiation reaction correlated with an enhanced chromosome radiation response.Twelve patients with late radiation skin ulcers formed after courses of radiation therapy were chosen as a group of individuals with elevated skin radiosensitivity.Half of the venous blood samples from each donor were irradiated with 2 Gy trays; the other half remained unexposed.Using standard cytogenetic technique, lymphocyte cultures were prepared with all samples.On the metaphase preparations, all chromosome aberrations detectable without karyotype identification were scored.The frequency of various aberrations in each patient were compared with relevant mean values in healthy unexposed donors.In several patients, the frequency of one aberration type or another exceeded the control value significantly.Comparison of aberration patterns in irradiated and nonirradiated cultures and consideration of elapsed time after therapeutic exposures suggested that the observed increased aberration levels reflected individual features of the patients' radiosensitivity, rather than lesions induced by previous in vivo exposures.Therefore, the question of a correlation between skin and chromosome radiosensitivity can be answered positively.Analysis of the peculiarities of cellular distribution of aberrations and of the relative contribution of different aberration types in patients and healthy donors indicates that the investigation of in vitro-induced aberrations is more suitable for the assessment of individual radiosensitivity than the study of aberrations observed in unexposed cultures.
Potential causes and health effects of rising global food prices
Journal: BMJ (2009)

High food prices affect not only our pockets but also our health.Karen Lock and colleagues examine the cause of recent increases and discuss what can be done to minimise harm Large increases in food prices have occurred at many times and in many places throughout history.The recent increases differ in their global reach and degree of volatility.Between January 2006 and July 2008 global food prices rose by an average of 75%, causing an estimated 75 million additional people to become undernourished worldwide.We evaluate how several factors have contributed to rising food prices and analyse the potential consequences of these rises for food security and public health.As food prices are predicted to remain high for several years, we discuss policy responses that could help secure an affordable, healthy global food supply. How much have food prices risen?Global food prices began to rise in 2003, but the rate of increase accelerated greatly in 2006, with prices reaching record highs in mid2008 (fig 1⇓).1 2 The 14% increase in 2006 in the commodity food price index, an index of major commodity prices weighted by market share, was dwarfed by the 27% increase in 2007.Although prices fell in the second half of 2008, in January 2009 the food price index was still 26% above what it had been three years previously.However, beneath these aggregate figures, price trends in important global staples differ widely.Though the price increase for palm oil over five years was only 4%, wheat rose by 48%, bananas by 64%, and rice by 189%.
Autoimmunity in juvenile diabetics and their families.
Authors: G F Bottazzo, J I Mann, M Thorogood, J D Baum, D Doniach
Journal: BMJ (1978)

Pancreatic islet cell, thyroid, and gastric antibodies were studied in 116 young insulin-dependent diabetics and 257 relatives. Seventy-four per cent of the diabetics studied within three months of diagnosis had islet-cell antibodies but only 20% of those studied three years or more after diagnosis. Persistence of these antibodies was associated with a high prevalence of thyrogastric autoimmunity, which suggests that some cases have an aetiology similar to that of "polyendocrine" autoimmune disease. Retinopathy or nephropathy, or both, was present in 10 diabetics, who were all members of "autoimmune" families, in which one or more members had organ-specific antibodies. Nine of the 10 healthy relatives with islet-cell antibodies and all families with more than one diabetic were also in this autoimmune group. These data suggest that an autoimmune factor may contribute to juvenile diabetes and that such autoimmune diabetes has a tendency to run in families and may be more likely to cause complications.
Abstract 101: <i>FHL2</i> -null Mice Showing Less Cardiac Remodeling
Authors: Pao Hsien Chu
Journal: Circulation Research (2017)

The four and a half Lin11, Isl-1 and Mec-3 (LIM) domain protein 2 (FHL2) is a member of the four and a half LIM domain-only (FHL) gene family, and has been shown to play an important role in cardiac remodeling. Here, we tested the hypothesis that isoproterenol-induced myocardial fibrosis in mice lacking FHL2 is related to resistant to myocardial fibrosis. We compared the cardiac phenotypes of FHL2 -null mice. Extra-cellular matrix remodeling and apoptosis are examined to determine the roles of FHL2 on cardiac fibrosis induced by isoproterenol. Compared to wild type littermates, FHL2 -null mice exhibited lower mortality. Masson’s Trichrome and silver stains showed significantly less severe ventricle fibrosis in FHL2-null mice. In addition, FHL2 -null mice exhibited lower levels of TGF-β, collagen I/III, but higher membrane-type matrix metalloproteinase-1 (MT1-MMP/MMP-14) during cardiac remodeling. This study shows that alternations of FHL2 might be implicated in the pathogenesis of cardiac fibrosis and suggests FHL2 as novel targets for cardiac fibrosis therapy. Further studies are required to define the mechanism by which FHL2 modulates cardiac remodeling.
BACTERIOLOGIC EXAMINATIONS REGARDING MEMBRANOUS CROUP, BY THE NEW YORK CITY BOARD OF HEALTH.
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
QLIF-33. ACTIVE COPING STRATEGIES ARE ASSOCIATED WITH IMPROVED OVERALL SURVIVAL IN NEWLY DIAGNOSED GLIOBLASTOMA: A PROSPECTIVE STUDY
Authors: Sied Kebir, Michael Niessen, Alexandra Kellner, Volker Tschuschke, Ulrich Herrlinger, Martin Glas
Journal: Neuro-Oncology (2017)

The impact of psychosocial variables on the survival of cancer is discussed controversially. In a prospective study, we investigated whether the quality of coping strategies are of prognostic value in newly diagnosed glioblastoma. In a prospective study, patients with newly diagnosed glioblastoma underwent audiotaped interviews immediately following surgery and before initiating radiochemotherapy. The patients’ coping strategies were then identified from each interview using the Ulm Coping Manual that describes 34 different coping strategies. An exploratory factor analysis was conducted to assess patterns of coping strategies that reflect the same underlying general coping mechanism (also known as factor). These factors are characterized by a set of highly correlated coping strategies. Patients who are highly associated (loaded highly on) with a specific factor were compared against those with low loadings. We compared overall survival (OS) between patients loading highly on a specific factor and those with negative loadings. A Cox regression analysis served to detect independent prognostic variables. Eighteen patients were eligible for interviewing. Six factors have been retained based on the amount of variation they explain in all coping strategies. Among those, factor 1 (F1) explained the overall highest amount of variation and was characterized almost exclusively by high loadings of active coping strategies, including taking the initiative, problem analysis, emotional support, optimism/hope, and active compliance with factor loadings ranging from 54%-92%. The high F1 loadings group had a particularly high median OS (24.1 months) as compared to the one with low F1 loadings (median OS, 10.6 months, p=0.0002). In a multivariable Cox regression analysis, F1 emerged as a prognostic factor (p<0.001) independent of canonical prognostic markers including age, Karnofsky performance score, extent of resection, and O6-methylguanin-DNA-methyltransferase (MGMT). Exploitation of coping mechanisms may offer a possible novel avenue for glioblastoma treatment. Further exploration in a larger trial is warranted.
Die Epidemiologie des Typhus abdominalis unter besonderer Berücksichtigung des Bact. typhi flavum.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
EXPERT MEDICAL TESTIMONY IN JURY TRIALS.
Journal: JAMA (1892)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Delirium Tremens
Authors: Martin H. Halvorsen
Journal: JAMA (1965)

<h3>To the Editor:—</h3> In regard to Dr. Marvin Block's answer to the question on "Prevention of Delirium Tremens" (QUESTIONS AND ANSWERS,<i>JAMA</i><b>191</b>:779, [March 1] 1965), I have been interested in the theoretical and practical aspects of alcohol-induced hallucinated states for many years. I am familiar with the old controversy about whether or not delirium tremens is truly an alcohol withdrawal phenomenon or something far more obscure in terms of primary toxic effects, vitamin deficiency, and what not. No clinician familiar with the problem will argue the point for long: the alcoholdeprived patient is the delirium tremens patient. Ergo, to prevent delirium tremens give alcohol. At a private hospital devoted to treatment of alcoholism, I have consulted with severe, chronic, heavy drinkers who arrive in all stages of unselected states of over-indulgence. We could not demonstrate one genuine case of delirium tremens per year! Every patient is given some